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The possibility that the cerebral ventricles can dilate without any increase in the pressure of the
cerebrospinal fluid (CSF) was recognized in 1935 by Penfield who reported a patient in whom “ . . . the
cerebrospinal fluid spaces are closed and the ventricles progressively enlarge without the measured
intraventricular pressure rising above 150 to 200 mm of water” [1]. However, the normal pressure
hydrocephalus (NPH) syndrome was first described by Hakim in 1964 in his PhD thesis and by Hakim
and Adams in 1965 [2,3]. In their seminal paper, Hakim and Adams reported on three patients with
ventriculomegaly and severe dementia—two posttraumatic and one idiopathic—associated with a
CSF lumbar pressure below 180 mmH2O (14 mmHg) that significantly improved after implanting
a ventriculoatrial shunt [2,3]. In a second paper published the same year, they added three similar
patients and proposed the term NPH to define a syndrome in which patients presented with cognitive
deterioration, gait disturbances, and urinary incontinence together with ventriculomegaly and normal
CSF pressure [4]. They emphasized that these patients had treatable dementia and that it was essential
to differentiate them from patients with “presenile or senile” dementia or Alzheimer’s disease in
whom dilatation of the ventricles could be a consequence of an exvacuo brain atrophy [3,4]. After the
initial reluctance from neurosurgeons and neurologists to accept this syndrome, it was progressively
acknowledged as one treatable cause of dementia. Nevertheless, ongoing controversies about the best
screening tools, the most appropriate diagnostic work-up, and the best predictors of outcome in NPH
still exist [5].
Two patient phenotypes in the NPH syndrome can be found: (1) patients with a known etiology
(subarachnoid hemorrhage, head injury, brain tumors, etc.) and (2) those without any recognized
cause, labeled as idiopathic NPH (iNPH) [5]. Over the past two decades, Alzheimer’s disease (AD)
and Alzheimer’s disease-related dementias have been the target for clinicians and policymakers
due to the significant increase in the number of cases as a result of the worldwide growth in the
elderly population [6]. Hakim et al. suggested that about 10% of dementia patients could have an
iNPH [5]. In a systematic review of the epidemiology of iNPH, Zaccaria et al. reported an incidence
ranging from 1.8 to 7.3/100,000 per year and a prevalence ranging from 10 to 29/100,000 [7]. Because
iNPH affects <1 in 2000 citizens, according to the European normative, iNPH could be considered
a “rare disease”. However, the methodological and clinical heterogeneity of the studies addressing
this topic does not allow us to draw adequate conclusions on the true epidemiology of iNPH [7].
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Until large population-based studies with homogeneous diagnostic criteria are conducted, the true
incidence/prevalence of NPH will not be known, but both are probably largely underestimated.
The clinical symptoms of iNPH may be improved temporarily by evacuating CSF using a lumbar
puncture/drainage; however, the only definite treatment is a CSF diversion with a ventriculoatrial,
ventriculoperitoneal, or a lumboperitoneal shunt [8]. The persistent reluctance of many neurologists
and neurosurgeons in shunting patients with iNPH is usually justified by the relatively high number of
non-responders, the morbidity associated with the surgery, and the lack of “evidence-based” support
for clinical decision making. The first influential study on the treatment of NPH was published by
Vanneste et al. in 1992 [9]. In this four-center retrospective study and literature review, the authors
reported that marked improvements occurred in only 15% of the shunted iNPH patients, and serious
adverse events were found in 8.6% of them [9]. They concluded that “The common opinion that
improvement of clinical importance in presumed iNPH after a shunt will occur in 35 to 50% is optimistic
and may be influenced by a publication bias” [9]. In an editorial commenting on this study, Vanneste
remarked that “Most neurosurgeons will not submit these patients to the risks of a shunting procedure
because the chance of a postoperative disaster is higher than that of an unexpected surgical success” [10].
Despite very strong opinions such as this one and the lack of randomized-placebo controlled clinical
trials that unequivocally justify the benefit of surgery in iNPH patients [11], shunting patients with
NPH is a common surgery conducted world-wide with two available prospective multicenter studies
showing that most patients who are selected by clinical and neuroradiological findings benefit from
surgery with an acceptable risk [12–14].
A new wave of therapeutic nihilism has recently resurged. Saper, the Editor-in-Chief of the Annals
of Neurology, in an editorial commenting on the American Academy of Neurology guidelines for
iNPH released in 2015, asked neurologists to “ . . . seriously consider calling a moratorium on shunting
procedures for iNPH until evidence of efficacy is obtained in a rigorous, randomized, placebo-controlled
trial” [15]. Despite this highly polarized view, we could use Saper’s own words to define our position
as guest editors of this special issue: “but my own reading of the literature and my own clinical
experience had indicated that the evidence to support this statement is very weak” [15]. Although not
placebo-controlled, the available evidence justifies surgery for iNPH patients. In addition, we believe
that not enough clinical equipoise exists among neurologists and neurosurgeons to conduct the
“rigorous, randomized, placebo-controlled trial” that Saper claims as a basic requirement to continue
shunting patients with iNPH. However, these controversial aspects surrounding the NPH syndrome
and its treatment merit careful consideration and will be discussed in depth in this special issue.
Nowadays, three clinical guidelines have been released for the management of NPH patients:
(1) the international guidelines published in 2005 [16], (2) the Japanese guidelines written in 2012 [8],
and (3) the American Academy of Neurology guidelines released in 2015 [17]. The three guidelines
contain recommendations for the diagnosis and management of patients with suspected NPH, but they
are quite heterogeneous in their methodological quality when evaluated by using the widely accepted
AGREE-II tool [18]. Furthermore, the international guidelines published in 2005 have not been
upgraded yet and therefore do not incorporate some recent relevant studies, such as the SINPHONI-2
trial [13]. Many prospective, non-randomized, single-center studies conducted in centers with
interest and research programs in NPH have reported above-average good outcomes in iNPH even
in patients considered as ‘bad candidates’ for shunting [14,19–21]. Despite the usual limitations that
uncontrolled clinical trials have, including selection bias and confounding and less generalizable
results, the significant differences in these reported outcomes compared to highly-cited studies raises
some relevant questions, such as the volume of patients treated by the hospital/individual surgeon
and the clinical outcomes for different surgical procedures [22]. In addition, two relevant multicenter
studies have reported better-than-expected outcomes. The first was the European multicenter study on
iNPH (Eu-iNPH) that enrolled patients who were selected only by clinical and radiological criteria [12].
In this prospective study, 142 patients with iNPH included in 13 European centers were shunted with
an adjustable valve [12]. In the Eu-iNPH, 84% of shunted patients showed improvements one year after
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surgery when evaluated by an ad-hoc NPH scale, and the outcome was also good in 69% of them when
evaluated by the less sensitive and motor-oriented modified Ranking Scale [12]. The second study
was the SINPHONI-2 trial conducted in Japan [13]. The SINPHONI-2 was a randomized open-label
trial, in which two arms were defined to avoid ethical issues: (1) in the first, patients were shunted
immediately after randomization with a lumboperitoneal shunt with gravitational control and (2)
in the control group, patients underwent the same surgery after a 3-month delay [13]. The primary
endpoint was an observed improvement of at least one point on the modified Rankin Scale (mRS)
at three months after randomization. Improvements did occur in 65% of the immediately shunted
patients compared with only 5% of the patients in the delayed shunted group [13].
These new results make it difficult to justify clinical equipoise and therefore the design of
randomized placebo-controlled clinical trial as claimed by Saper [15] but should open new research
lines dedicated to understanding the reasons why ~20% of patients were non-responders. As remarked
by Fasano et al. in a proposed roadmap for research in NPH, “The time has come to start to effectively
rethink NPH and determine the many molecular and biological disruptions behind a disorder that,
for too long, has remained idiopathic” [23].
Patients with secondary NPH are easily identified in all clinical settings. However, the detection of
patients with iNPH remains challenging in an aging society with a high prevalence of cognitive decline
and dementia and the associated burden to patients, families, and healthcare services. To improve
the treatment of iNPH patients, good screening tests for early detection of potential candidates at the
primary care level that might be referred early to neurologists are needed. As remarked by Fasano et al.,
the need to improve the screening tools and to reach consensus for a universally-accepted and validated
NPH scale that covers all the domains of the syndrome exists [23]. A consensus is also needed on the
neuroimaging criteria needed to move the screened patients to the category of possible iNPH and
therefore refer them to a tertiary center for further evaluations.
At the tertiary centers, we need to clarify whether more sophisticated tests, such as the continuous
infusion, Marmarou’s, and tap tests, clinical response to a lumbar drain, intracranial pressure monitoring,
and/or more complex and technically-demanding studies, such as compliance and CSF pulse-pressure
analysis are needed. These tests might provide additional relevant information for confirming iNPH or
predicting the response to a shunt. In this context, we need reproducible biomarkers to detect/exclude
concomitant neurodegenerative diseases that can influence a patient’s response to a shunt (Alzheimer’s
disease, progressive supranuclear palsy, Lewy body dementia) [23].
Once the patients have been diagnosed with iNPH, we need consensus to define the optimal
shunt assembly for treating these patients. We believe that the “one-size-fits-all” approach in some
multicenter clinical trials in which a fixed-opening differential-pressure valve (DPV) was implanted [9]
or the wide variability in the shunt hardware used in most single-center studies may justify the reported
differences in outcomes and the variability in the described complications. The reluctance of the
neurosurgical community to incorporate new technologies, such as adjustable-valves and especially,
devices for gravitational control, into shunt designs exists because there are no randomized clinical
studies that justify these changes. As a result, the neurosurgery community sticks to old DPV designs
based on the misleading concept of low-, medium-, and high-pressure DPV “because they still work”.
This uncritical thinking needs to be addressed.
In this focused review for the Journal of Clinical Medicine, we gathered a group of experts
with a significant track record in clinical management and research in the field of idiopathic normal
pressure hydrocephalus (iNPH) to discuss some of the gaps and ongoing controversies. We believe
that evidence-based medicine (EBM) was a paradigm shift in medicine, but we are also concerned with
a dogmatic and unrealistic application of EBM to complex diseases, such as iNPH. We fully agree with
the statement written in the Trisha Greenhalgh paper on EBM that states, “When medicine is reduced
to the dispassionate application of scientific evidence, we will necessarily make worse judgments,
not better ones” [24].
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We, the guest editors, have enjoyed organizing this Special Issue and are rewarded by the
final result of the joint effort. We hope this special issue will accomplish the goal of presenting
focused peer-reviewed papers addressing some controversial areas that can be helpful for neurologists,
neurosurgeons, and family practitioners when managing iNPH patients.
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